Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Updates on Chronic Lymphocytic Leukemia
share announcement

Updates on Chronic Lymphocytic Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 4398

Special Issue Editors

Prof. Dr. Carmine Selleri

E-Mail Website
Guest Editor
Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy
Interests: immunity; immunotherapy; leukemia
Special Issues, Collections and Topics in MDPI journals
Dr. Giovanni D'Arena

E-Mail Website
Guest Editor
Hematology, P.O. S. Luca, ASL Salerno, Vallo della Lucania, Italy
Interests: chronic lymphocytic leukemia; targeted therapy; leukemia
Dr. Luca Laurenti

E-Mail Website
Guest Editor
Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy
Interests: chronic lymphocytic leukemia; targeted therapy; leukemia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is a heterogeneous group of clonal B-cell lymphoproliferative diseases with various clinical courses and biological features, where microenvironment, phenotypic, chromosomal, and molecular alterations concur with disease development and progression. Risk stratification and prognostication is performed using the CLL-International Prognostic Index, which combines clinical, chromosomal, molecular, and serological alterations and can help in clinical management and therapeutic decisions. Indeed, the discovery of novel disease biomarkers can also identify novel targeted therapies that can markedly improve clinical outcomes of CLL, as described for ibrutinib, idelalisib, and venetoclax.

We are pleased to invite you to a Special Issue of Cancers on the topic of Updates on Chronic Lymphocytic Leukemia.

This Special Issue focuses on novel diagnostic and prognostic markers and recent therapeutic advances of CLL. Articles shining a light on the mechanisms of drug resistance and disease progression are also welcome. Authors are encouraged to submit their original research studies concerning this topic. Review articles will also be taken into consideration.

Topics include, but are not limited to, the following:

  • Recent development in molecular biomarkers predicting prognosis of CLL;
  • Minimal residual disease in CLL;
  • Targeted therapies and novel therapeutic strategies;
  • Recent advances in management of CLL;
  • Mechanism of drug resistance and novel therapies to overcome the resistance.

We look forward to receiving your contributions.

Prof. Dr. Carmine Selleri
Dr. Giovanni D'Arena
Dr. Luca Laurenti 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2461 KiB  
Article
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience
by Idanna Innocenti, Alberto Fresa, Annamaria Tomasso, Michela Tarnani, Laura De Padua, Giulia Benintende, Raffaella Pasquale, Eugenio Galli, Francesca Morelli, Diana Giannarelli, Francesco Autore and Luca Laurenti
Cancers 2023, 15(23), 5592; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15235592 - 26 Nov 2023
Viewed by 729
Abstract
Background: This monocentric retrospective study describes the treatment patterns and outcomes of chronic lymphocytic leukemia (CLL) patients. Methods: Adult CLL patients treated between 1992 and 2022 were included. The time to next treatment (TTNT) was defined as the time from the treatment’s start [...] Read more.
Background: This monocentric retrospective study describes the treatment patterns and outcomes of chronic lymphocytic leukemia (CLL) patients. Methods: Adult CLL patients treated between 1992 and 2022 were included. The time to next treatment (TTNT) was defined as the time from the treatment’s start to the start of a subsequent therapy or death. The time to next treatment failure or death (TTNTF) was defined as the time from treatment discontinuation to the discontinuation of a subsequent therapy or death. Results: Of 637 registered patients, 318 (49.9%) received treatment. We evaluated 157 cBTKi-exposed, 34 BCL2i-exposed cBTKi-naïve, and 26 double-exposed patients. The five-year TTNT values in the cBTKi-exposed patients were 80% (median NR), 40% (median 40 months), and 21% (median 24 months) months in the first line (1L), second line (2L), and beyond the second line (>2L), respectively (p < 0.0001). The five-year TTNT values in the BCL2i-exposed patients were 83% (median NR), 72% (median NR), 12% (median 28 months) in the 1L, 2L, and >2L, respectively (p = 0.185). The median TTNTF was 9 months (range 1–87) after cBTKi and 17 months (range 8–49) after both a cBTKi and BCL2i. Conclusions: This study suggests that, in CLL patients, the earlier we used targeted therapies, the better was the outcome obtained. Nonetheless, the poor outcomes in the advanced lines of therapy highlight the need for more effective treatments. Full article
(This article belongs to the Special Issue Updates on Chronic Lymphocytic Leukemia)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 314 KiB  
Review
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
by Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo and Alessandra Tedeschi
Cancers 2023, 15(5), 1504; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15051504 - 27 Feb 2023
Cited by 11 | Viewed by 3136
Abstract
Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a [...] Read more.
Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially for high-risk patients, and include BTK inhibitor combinations with BCl2 inhibitors with or without anti-CD20 monoclonal antibodies. Finally, new mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL. Full article
(This article belongs to the Special Issue Updates on Chronic Lymphocytic Leukemia)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop